Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Maxamine histamine receptor agonist plus low-dose interleukin-2: Phase II data; Phase II and III ongoing

MMP said 15 of 26 patients in first remission remain disease-free; 13 patients (65

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE